APOC3 and metabolic syndrome: Other two phase 2 studies are the SHASTA-2 (Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia) trial enrolling patients with severe hypertriglyceridemia (NCT04720534) and the MUIR (Study of ARO-APOC3 in Adults With Mixed Dyslipidemia) trial on patients with mixed dyslipidemia.